Moderna

Moderna's high financial strength score of 80/100, while seemingly robust, requires careful interpretation in light of its current operational losses. This score is largely attributable to the substantial cash reserves accumulated during the peak of the COVID-19 vaccine sales, which provide a strong liquidity buffer.

The current ratio of 3.93x is excellent, indicating a healthy ability to cover short-term liabilities with current assets. However, this strength is being rapidly depleted by severe cash burn, as evidenced by a TTM Net Income of $-7.20B and a TTM Free Cash Flow of $-10.54B.

While the company possesses significant capital, its operational activities are not generating cash, but rather consuming it at an alarming rate.

Without a clear path to profitability and positive cash flow generation from its pipeline, this financial strength, though high now, represents a finite resource that is steadily diminishing, posing a significant long-term risk if the current burn rate persists.